Sponsor	Phase
University Tunis El Manar	NA
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE2
University of North Carolina, Chapel Hill	PHASE4

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Amphastar Pharms Inc	DUOCAINE	bupivacaine hydrochloride; lidocaine hydrochloride	INJECTABLE;INJECTION	021496-001	May 23, 2003		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 2, 2026

Bupivacaine hydrochloride and lidocaine hydrochloride are mature, multisource local anesthetics with low unit prices, high procedural demand, and limited conventional patent protection. Their financial trajectories are driven by manufacturing reliability, hospital contracting, shortages, dosage-form differentiation, and branded delivery systems rather than by core-molecule exclusivity. Lidocaine has the broader market and more diversified applications. Bupivacaine has greater value concentration in regional anesthesia, pain procedures, and premium extended-release products such as EXPAREL.

Bupivacaine Hydrochloride and Lidocaine Hydrochloride Market Dynamics and Financial Trajectory

What are bupivacaine hydrochloride and lidocaine hydrochloride used for?

Bupivacaine hydrochloride and lidocaine hydrochloride are amide local anesthetics used to block sodium channels and interrupt nerve conduction.

Drug	Principal clinical uses	Typical positioning
Bupivacaine hydrochloride	Epidural anesthesia, peripheral nerve blocks, infiltration, spinal anesthesia, postoperative analgesia	Longer duration; higher cardiotoxicity concern at excessive exposure
Lidocaine hydrochloride	Local infiltration, regional anesthesia, dental anesthesia, epidural use, topical anesthesia, intravenous antiarrhythmic therapy	Faster onset; shorter duration; broader route and setting coverage

Lidocaine hydrochloride is sold in injectable, topical, transdermal, oral, dental, ophthalmic and otic products. Bupivacaine hydrochloride is concentrated in injectable products, including single-dose vials, ampules, prefilled syringes and premixed solutions.

FDA-approved labeling identifies the drugs as established anesthetic products with multiple generic manufacturers and dosage forms. The active ingredients are small-molecule chemical entities, so biosimilar regulation does not apply.[1][2]

How large are the bupivacaine and lidocaine markets?

No major originator publicly reports standalone global revenue for unbranded bupivacaine hydrochloride or lidocaine hydrochloride. Market value is fragmented across hospital purchases, physician-office procedures, dental channels, retail topical products and compounded or contract-manufactured products.

Lidocaine has the larger addressable market because it is used across more therapeutic categories and dosage forms. Bupivacaine has a narrower volume base but can generate higher value per procedure when used in regional anesthesia or advanced delivery systems.

Market structure

Market characteristic	Bupivacaine hydrochloride	Lidocaine hydrochloride
Core molecule status	Mature generic	Mature generic
Primary channel	Hospitals, ambulatory surgery centers, anesthesia providers	Hospitals, dental offices, physician offices, retail and specialty channels
Volume profile	Procedure-linked and concentrated	Broad, recurring and highly diversified
Price structure	Low-cost generic injectable; premium for extended-release formulations	Low-cost generic injectable and topical products; differentiated prices for branded patches and systems
Supply sensitivity	High because injectable products require sterile manufacturing	High for injectables, lower for diversified topical products
Patent dependence	Low for base drug	Low for base drug
Growth drivers	Surgical volume, regional anesthesia, opioid-sparing protocols, drug shortages	Procedure volume, dental demand, topical pain products, antiarrhythmic use and shortage-driven substitution

Demand is tied to surgical and procedural activity rather than chronic patient enrollment. Ambulatory surgery, emergency care, dental procedures and regional anesthesia protocols support recurring demand. Opioid-sparing pathways have increased interest in local anesthetics, although they do not automatically translate into higher revenue for low-priced generic injections.

What is the financial trajectory for bupivacaine hydrochloride?

The base bupivacaine hydrochloride market has a mature-to-stable financial profile. Revenue growth is generally volume-led and can be offset by generic price compression.

The key financial variables are:

Surgical and procedural volume.
Contract wins with hospitals and group purchasing organizations.
Manufacturing capacity for sterile injectable products.
Product availability during shortages.
Mix between commodity bupivacaine and premium extended-release products.
Regulatory compliance costs at sterile manufacturing facilities.

Bupivacaine hydrochloride pricing is vulnerable to bidding pressure because hospitals can source from multiple approved suppliers. However, the market is less economically commoditized when there are supplier exits, manufacturing interruptions or FDA-recognized shortages. In those periods, revenue can rise through temporary price increases or higher share, but the benefit may be offset by remediation, expedited production and inventory costs.

The most important commercial distinction is between conventional bupivacaine hydrochloride and long-acting delivery products. EXPAREL, Pacira BioSciences' liposomal bupivacaine product, uses a DepoFoam delivery system and is not equivalent to conventional generic bupivacaine hydrochloride. Its commercial economics are based on formulation, delivery technology, clinical positioning and patent protection rather than the base salt alone.[3]

Bupivacaine financial scenarios

Scenario	Volume	Price	Financial effect
Stable generic market	Stable to modest growth	Declining or flat	Low-to-moderate revenue growth, margin pressure
Supplier shortage	Temporarily higher	Potentially higher	Short-term revenue uplift with supply and compliance costs
New hospital contract	Higher share	Lower contracted price	Revenue growth with narrower gross margin
Increased regional anesthesia use	Higher	Usually stable	Favorable operating leverage
Shift to premium liposomal products	Conventional volume may decline	Premium product price higher	Value moves from commodity drug to protected delivery system

What is the financial trajectory for lidocaine hydrochloride?

Lidocaine hydrochloride has a more diversified and resilient revenue base than bupivacaine hydrochloride. Injectable lidocaine is a hospital product, while topical and transdermal forms create additional retail and specialty revenue streams.

Generic injectable lidocaine faces sustained price competition. Branded or differentiated products can preserve pricing through formulation, delivery technology, packaging, indication-specific positioning or channel control. Examples include lidocaine patches, topical systems, dental cartridges and combination products. These products should not be treated as interchangeable with injectable lidocaine hydrochloride when assessing market value.

Lidocaine's long-term market trajectory is likely to remain volume-driven. Revenue growth depends more on expanded procedural use and product mix than on price increases. The broad range of dosage forms reduces dependence on any one customer segment, but it also increases regulatory and manufacturing complexity.

Lidocaine revenue drivers

Dental procedure volumes.
Emergency department and outpatient procedure activity.
Topical treatment demand.
Chronic pain and postherpetic neuralgia products.
Hospital and ambulatory surgery contracts.
Availability of injectable presentations.
Use as an antiarrhythmic in acute-care settings.
Generic competition in injectable and topical products.

Lidocaine's financial exposure to shortages can be material because hospitals use it across multiple departments. A disruption in one injectable presentation can shift demand to different concentrations, vial sizes, preservatives or suppliers. That substitution can produce temporary revenue gains for manufacturers with available inventory.

What patents protect bupivacaine hydrochloride and lidocaine hydrochloride?

The base molecules are long off-patent. The original composition-of-matter and early formulation protections for bupivacaine and lidocaine expired many years ago. Current commercial value generally does not depend on patent exclusivity for standard injectable hydrochloride products.

Patent protection by product category

Product category	Core patent position	Commercial relevance
Standard bupivacaine HCl injection	Legacy patents expired	Generic competition
Standard lidocaine HCl injection	Legacy patents expired	Generic competition
Lidocaine topical products	Product-specific formulations, delivery systems or combinations may be protected	Moderate for differentiated brands
Bupivacaine liposomal products	Formulation, composition, manufacturing and method-of-use patents may apply	High for branded extended-release products
Premixed or prefilled presentations	Device, packaging or manufacturing claims may apply	Usually limited unless tied to a differentiated system
Compounded preparations	Generally outside conventional branded patent economics	Regulatory and quality risk more important

Patent analysis must separate the active ingredient from the finished product. A patent covering liposomal bupivacaine, a transdermal lidocaine system or a device does not create exclusivity over ordinary bupivacaine hydrochloride or lidocaine hydrochloride injection.

When did bupivacaine and lidocaine lose exclusivity?

Both drugs lost meaningful composition-of-matter exclusivity decades ago. Their current FDA market access is based on abbreviated new drug applications, approved drug applications and legacy products rather than active molecule-level exclusivity.

Exclusivity issue	Bupivacaine hydrochloride	Lidocaine hydrochloride
New chemical entity exclusivity	Expired	Expired
Core composition patent	Expired	Expired
Standard generic entry	Established	Established
Current five-year exclusivity risk	None for the old molecule	None for the old molecule
Biosimilar pathway	Not applicable	Not applicable
Main barrier to entry	Sterile manufacturing and supply reliability	Sterile manufacturing, formulation complexity and channel access

A newly approved delivery system can receive separate regulatory exclusivity or patent protection even when its active ingredient is old. That distinction is central to the commercial analysis of liposomal bupivacaine and branded lidocaine delivery products.

What is the FDA and Orange Book status of these drugs?

FDA-approved standard bupivacaine hydrochloride and lidocaine hydrochloride products are generally listed through multiple approved applications and generic equivalents. The Orange Book is most relevant for approved drug products with listed patents and therapeutic-equivalence information, not for determining whether the old active ingredients remain patent-protected.[4]

The practical regulatory questions are:

Whether the product is approved for the intended route and concentration.
Whether the manufacturer has an active application.
Whether the dosage form is therapeutically equivalent to the reference product.
Whether listed patents apply to the specific product.
Whether the product is subject to an FDA shortage notice.
Whether the product is manufactured under compliant current good manufacturing practices.

For generic injectables, manufacturing quality is often more commercially important than patent status. FDA warning letters, manufacturing remediation, product recalls and facility outages can change market share rapidly.

Which companies compete in bupivacaine and lidocaine?

Competition varies by country and presentation. Major generic and injectable manufacturers have included Fresenius Kabi, Pfizer, Hikma Pharmaceuticals, Sagent Pharmaceuticals, Eugia and other regional suppliers, subject to product-specific approvals and market participation. B. Braun and pharmaceutical distributors also participate in hospital supply channels for selected presentations.

Pacira BioSciences is distinct from conventional generic suppliers because its principal bupivacaine franchise is EXPAREL, an extended-release liposomal formulation. Its economics rely on branded adoption, surgical protocols, reimbursement and intellectual property rather than commodity pricing.[3]

Competitive position depends on:

Number of approved suppliers.
Vial and concentration availability.
Contracted hospital share.
Shortage history.
Manufacturing location and redundancy.
Ability to supply preservative-free or specialty presentations.
Distributor and group purchasing organization relationships.

Are there Paragraph IV challenges for bupivacaine or lidocaine?

Paragraph IV litigation risk is limited for standard bupivacaine hydrochloride and lidocaine hydrochloride because the core drugs are long off-patent. A Paragraph IV challenge can still arise for a branded formulation, device, delivery system, method of use or manufacturing process.

Relevant litigation patterns

For conventional generic injections, the principal legal risks are usually:

Product liability.
Antitrust allegations involving generic supply or contracting.
Manufacturing and quality disputes.
ANDA approval delays caused by formulation or labeling issues.
Patent disputes involving a branded delivery technology.

For extended-release bupivacaine, generic applicants may challenge patents listed against the branded product. These disputes can involve formulation claims, drug-release profiles, manufacturing processes and surgical indications. A successful challenge could accelerate competition, while a settlement could establish a later generic launch date.

No broad molecule-level Paragraph IV barrier protects ordinary bupivacaine hydrochloride or lidocaine hydrochloride injection.

What formulation patents protect these drugs?

Formulation and delivery patents are the main source of potential value.

Bupivacaine formulation protection

Potentially protectable technologies include:

Liposomal encapsulation.
Controlled-release particles.
Multivesicular delivery systems.
Sustained-release depots.
Combination products containing multiple anesthetics.
Premixed solutions with specialized stability profiles.
Device-enabled regional anesthesia systems.

EXPAREL's commercial differentiation is based on liposomal delivery and extended release. Pacira's patent and regulatory strategy has focused on the product formulation, manufacturing process and approved uses, rather than exclusivity over bupivacaine itself.[3]

Lidocaine formulation protection

Potentially protectable technologies include:

Transdermal patches.
Topical gels, creams and sprays.
Metered-dose delivery devices.
Sustained-release systems.
Dental cartridges and specialty packaging.
Combination products.
Ophthalmic and mucosal formulations.

These rights are product-specific. They generally do not prevent manufacturers from selling conventional lidocaine hydrochloride injection.

What generic entry risks exist?

Generic entry risk is high for ordinary injectable products and moderate for differentiated delivery systems.

Risk area	Bupivacaine HCl	Lidocaine HCl
New generic injection entry	High	High
Price erosion	High	High
Shortage-driven share volatility	High	High
Patent barrier for base drug	Low	Low
Formulation patent risk	Moderate for extended-release products	Moderate for patches and specialty systems
Manufacturing barrier	High	High
Biosimilar competition	None	None
Substitution risk	Moderate, depending on procedure	High across multiple local-anesthetic uses

Hospitals may switch suppliers rapidly when products are therapeutically substitutable and inventory is constrained. That creates recurring share volatility for manufacturers with weak supply reliability.

How do bupivacaine and lidocaine compare commercially?

Lidocaine is the broader and more diversified commercial market. Bupivacaine has stronger exposure to anesthesia protocols and regional blocks, with greater upside from premium extended-release products.

Metric	Bupivacaine hydrochloride	Lidocaine hydrochloride
Market breadth	Narrower	Broader
Generic price pressure	Severe	Severe
Premium formulation opportunity	High through long-acting delivery	High through topical and transdermal systems
Clinical duration	Longer	Shorter
Primary financial risk	Commodity pricing and sterile supply	Commodity pricing, broad substitution and channel fragmentation
Commercial moat	Manufacturing reliability and differentiated delivery	Product format, distribution and brand differentiation
Patent value	Concentrated in extended-release products	Concentrated in specialty formulations and devices

What licensing deals affect the market?

The largest economically relevant licensing issue is the technology behind premium delivery systems rather than the base hydrochloride salts. Pacira commercialized liposomal bupivacaine using the DepoFoam delivery platform originally associated with SkyePharma, later acquired by Pacira.[5]

For standard bupivacaine hydrochloride and lidocaine hydrochloride, public licensing economics are generally limited because generic manufacturers rely on established active pharmaceutical ingredient sources, contract manufacturing arrangements and commercial supply agreements. These arrangements can affect gross margin and supply continuity but usually do not create durable molecule-level exclusivity.

What geographic markets offer the strongest opportunity?

The United States offers the highest commercial value for branded delivery systems and hospital injectable contracts, but it also has significant pricing pressure from group purchasing organizations and generic competition.

Europe has extensive generic use and country-specific reimbursement and tender systems. Price erosion can be rapid after multiple suppliers enter.

Emerging markets may offer volume growth for injectable anesthetics, but pricing, local manufacturing requirements, registration complexity and distributor dependence reduce predictability.

Geographic considerations

United States: strongest premium-product opportunity; high generic contracting pressure.
Western Europe: mature demand; tender-driven pricing.
Japan: regulated pricing and established hospital use.
China: growing procedure volumes with increasingly competitive procurement.
Latin America: variable registration, reimbursement and distributor economics.
Middle East and Africa: supply reliability and public procurement are central.

What manufacturing and intellectual-property barriers matter most?

Sterile injectable production is the principal operational barrier. Manufacturers must maintain validated aseptic processes, reliable container-closure systems, qualified active-ingredient supply and compliance with FDA and comparable international requirements.

Important barriers include:

Aseptic filling capacity.
Sterility assurance.
Extractables and leachables control.
Container and closure availability.
Preservative-free manufacturing capability.
Concentration and presentation-specific validation.
Inspection readiness.
Redundant API and packaging suppliers.
Stability data for new presentations.

These barriers can protect incumbent market share temporarily even when no enforceable patent blocks generic entry.

What is the outlook for revenue and investment exposure?

The base drugs should be viewed as stable, low-growth pharmaceutical products rather than high-growth assets. Revenue expansion is most likely to come from procedure volume, supply disruptions, new presentations and premium delivery technologies.

Bupivacaine exposure is more attractive when linked to differentiated long-acting delivery, hospital protocol adoption or a reliable sterile manufacturing platform. Lidocaine exposure is more diversified but offers less molecule-level pricing power.

For investors and licensing teams, the relevant diligence questions are:

Is the revenue from conventional hydrochloride injection or a protected delivery system?
How many approved suppliers compete in each presentation?
What portion of sales depends on one hospital contract or group purchasing organization?
Has the manufacturer experienced recent shortages, recalls or FDA observations?
Are patent claims directed to the active ingredient, formulation, device or method of use?
Can a generic applicant design around the listed claims?
Is the product interchangeable under the applicable FDA approval?
Does the business have redundant sterile capacity?

Key Takeaways

Lidocaine hydrochloride has the larger and more diversified market.
Bupivacaine hydrochloride has stronger value concentration in regional anesthesia and long-acting delivery.
Both core molecules are long off-patent and exposed to generic price competition.
Neither product has biosimilar risk because both are small-molecule drugs.
Paragraph IV risk is low for standard injections but can be material for branded formulations and delivery systems.
Sterile manufacturing reliability is a greater barrier than base-molecule patent protection.
EXPAREL should be analyzed separately from conventional bupivacaine hydrochloride because its economics depend on liposomal delivery and branded exclusivity.
Financial growth is likely to be modest for commodity products and more substantial only in differentiated formulations, devices or shortage-constrained supply.

FAQs

Is bupivacaine hydrochloride more profitable than lidocaine hydrochloride?

Not as a commodity injectable. Bupivacaine can support higher strategic value when sold through extended-release or premium delivery systems, while lidocaine has broader volume and channel diversification.

Can a generic company launch standard lidocaine hydrochloride without licensing an originator?

Generally, standard lidocaine hydrochloride products can be developed through the applicable FDA abbreviated approval pathway without licensing the originator's expired molecule patents. Product-specific patents, formulation claims and regulatory requirements still apply.

Does a patent on EXPAREL block generic bupivacaine hydrochloride?

No. EXPAREL-related rights may affect a competing liposomal or extended-release product, but they do not ordinarily block conventional bupivacaine hydrochloride injection.

Which drug is more exposed to dental-market demand?

Lidocaine hydrochloride has greater dental exposure because dental cartridges, topical products and local infiltration are established uses. Bupivacaine is used selectively in longer-duration dental and oral-surgery applications.

What would cause a sudden increase in generic local-anesthetic revenue?

A manufacturer can gain revenue from a competitor's shortage, plant shutdown, recall, regulatory suspension or loss of hospital contract. The effect is often temporary and may reverse when supply normalizes.

References

U.S. Food and Drug Administration. (2023). Bupivacaine hydrochloride injection prescribing information. FDA.
U.S. Food and Drug Administration. (2023). Lidocaine hydrochloride injection prescribing information. FDA.
Pacira BioSciences, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.
Pacira Pharmaceuticals, Inc. (2011). Registration statement and company filings describing DepoFoam delivery technology and EXPAREL. U.S. Securities and Exchange Commission.

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	268
DailyMed Link:	bupivacaine hydrochloride; lidocaine hydrochloride at DailyMed

Bupivacaine hydrochloride; lidocaine hydrochloride - Generic Drug Details

What are the generic sources for bupivacaine hydrochloride; lidocaine hydrochloride and what is the scope of patent protection?

Summary for bupivacaine hydrochloride; lidocaine hydrochloride

Recent Clinical Trials for bupivacaine hydrochloride; lidocaine hydrochloride

Anatomical Therapeutic Chemical (ATC) Classes for bupivacaine hydrochloride; lidocaine hydrochloride

US Patents and Regulatory Information for bupivacaine hydrochloride; lidocaine hydrochloride